Exactly one week after the approval of PREZISTA™ (darunavir) by the American Food and Drug Administration (FDA) for the treatment of HIV/AIDS patients, we would like to reflect for a moment on this truly unique event and achievement. This is the first registration to be obtained for a product in Tibotec’s portfolio of anti-HIV/AIDS compounds. For many years a team of researchers at Tibotec put in a huge amount of work to make this milestone possible, and ultimately help patients all over the world. Exactly one week after the approval, PREZISTA™ is already being stocked by pharmacies in the US and the treatment is available in Europe through the Expanded Access program. 

Tibotec can be justifiably proud of this achievement, because it marks a highlight in the annals of Johnson & Johnson. Moreover, Tibotec itself is particularly appreciative of the good cooperation within Johnson & Johnson, which has been tremendously important for reaching this milestone. We are sincerely grateful to the personnel of Janssen Pharmaceutica for preparing the production in a very short timeframe, and for the strong support that we received from J&JPRD, Preclinical Development, Chem-Pharm Development, Global Clinical Operations and the Strategic Marketing teams.

As you can see, innovation and cooperation are the key to our success. Let us draw inspiration from this and concentrate fully on the further growth of our company.